Table 2.
Performance of the four autoantibodies in differentiating SLE patients from SS patients when specificity is set to 95%.
| Antibody | Cut Off | Sensitivity | Specificity | ||
|---|---|---|---|---|---|
| Anti-dsDNA | 100 | 52.78% | 90.80% | ||
| Anti-Nucl | 20 | 44.91% | 90.80% | ||
| Anti-Rib P | 20 | 17.59% | 97.70% | ||
| Anti-C1q | 20 | 15.28% | 98.85% | ||
| Specificity of assays is defined at 95% | |||||
| Anti-dsDNA | 188 | 41.20% | 95.40% | ||
| Anti-Nucl | 58 | 32.87% | 95.40% | ||
| Anti-Rib P | 20 | 17.59% | 97.70% | ||
| Anti-C1q | 20 | 15.28% | 98.85% | ||
Anti-dsDNA: anti-double-stranded DNA antibodies; Anti-Nucl: anti-nucleosome antibodies; Anti-Rib P: anti-ribosomal P antibodies; Anti-C1q: anti-c1q antibodies